Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans-Reference-Cited by-同舟云学术

Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ong Voon¹^ORCID,Wills Sarah²,Watson Deborah³,Sandison Taylor¹,Flanagan Shawn¹

Affiliation:

1. Cidara Therapeutics, Inc., San Diego, California, USA

2. Labcorp, Madison, Wisconsin, USA

3. QPS, LLC, Newark, Delaware, USA

Abstract

Rezafungin is a novel echinocandin being developed for treatment of candidemia and invasive candidiasis and for prevention of invasive fungal disease caused by Candida, Aspergillus , and Pneumocystis spp. in recipients of blood and marrow transplantation. Studies using [ 14 C]-radiolabeled rezafungin were conducted in rats, monkeys, and humans to characterize the mass balance, excretion, and pharmacokinetics of [ 14 C]-rezafungin and to evaluate relative amounts of rezafungin metabolites compared with parent drug.

Funder

Cidara Therapeutics

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01390-21

Reference19 articles.

1. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model

2. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae

3. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program